Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.

Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR.

Bone Marrow Transplant. 2013 Feb;48(2):269-77. doi: 10.1038/bmt.2012.132. Epub 2012 Jul 9.

2.

Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.

Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Reynolds C, Barlogie B, Kwak LW.

Bone Marrow Transplant. 2005 Aug;36(4):315-23.

PMID:
15968284
3.

Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.

Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A.

Blood. 1999 Jul 15;94(2):673-83.

4.

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.

Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R.

Blood. 1999 Apr 1;93(7):2411-9.

5.

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.

Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R.

Biol Blood Marrow Transplant. 2000;6(6):621-7.

6.

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.

Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM.

Br J Haematol. 2007 Nov;139(3):415-24.

PMID:
17910631
7.

Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.

Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A.

Leuk Lymphoma. 2006 Jan;47(1):29-37.

PMID:
16321824
8.

Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.

Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M.

Leukemia. 2004 Jan;18(1):139-45.

PMID:
14574332
9.

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.

Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL.

Lancet. 1995 Apr 22;345(8956):1016-20.

PMID:
7723498
10.

Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.

Davis TA, Hsu FJ, Caspar CB, van Beckhoven A, Czerwinsk DK, Liles TM, Taidi B, Benike CJ, Engleman EG, Levy R.

Biol Blood Marrow Transplant. 2001;7(9):517-22.

11.

Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.

Levenga H, Schaap N, Maas F, Esendam B, Fredrix H, Greupink-Draaisma A, de Witte T, Dolstra H, Raymakers R.

Biol Blood Marrow Transplant. 2010 Mar;16(3):320-32. doi: 10.1016/j.bbmt.2009.10.006. Epub 2009 Oct 14.

12.

Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.

Tyler EM, Jungbluth AA, Gnjatic S, O'Reilly RJ, Koehne G.

Cancer Immunol Res. 2014 Jun;2(6):547-58. doi: 10.1158/2326-6066.CIR-13-0174. Epub 2014 Mar 3.

13.

Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.

Zeis M, Steinmann J, Petrela E, Hartung G, Schmitz N, Uharek L.

Bone Marrow Transplant. 2001 Feb;27(3):279-85.

14.

Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.

Reichardt VL, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P.

Haematologica. 2003 Oct;88(10):1139-49.

15.

Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.

Röllig C, Schmidt C, Bornhäuser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S.

J Immunother. 2011 Jan;34(1):100-6. doi: 10.1097/CJI.0b013e3181facf48.

PMID:
21150718
16.

Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.

Zeis M, Frenzke H, Schmitz N, Uharek L, Steinmann J.

Bone Marrow Transplant. 2002 Feb;29(3):213-21.

17.

Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.

Li Y, Bendandi M, Deng Y, Dunbar C, Munshi N, Jagannath S, Kwak LW, Lyerly HK.

Blood. 2000 Oct 15;96(8):2828-33.

18.

Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.

Neeson P, Pan ZK, Paterson Y.

Cancer Immunol Immunother. 2008 Apr;57(4):493-505. Epub 2007 Sep 18.

PMID:
17876582
19.

Supplemental Content

Support Center